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Novel divergent methodology to access sp
3
-rich spirocyclic fragments is reported. Firstly, a robust modular synthesis of bis-alkene 
amino ester building blocks was developed. Three different carbocycles and six heterocycles were then constructed to assemble 
eight spirocycles. Importantly, strategic exit vectors were incorporated within each scaffold to aid fragment growth and were elabo-
rated via chemical modifications. Finally, computational methods demonstrate higher levels of rigidity, three-dimensionality and 
structural diversity of the library compared to a commercial collection. 
Since the rise of fragment-based drug discovery (FBDD) 
over two decades ago this strategy has proven particularly 






1. A). The success of this approach can be linked to two main 
benefits. Firstly, due to the considerably fewer number of pos-
sible fragment-sized molecules, the chemical space coverage 
of a relatively small fragment library is exceedingly more effi-
cient than that of a vast high-throughput screening (HTS) li-
brary. Secondly, fragment hits possess fewer but nonetheless 
high-quality binding interactions with the protein target, which 




Within this paradigm the generation of a suitable screening 
library is paramount. However, despite undoubted success of 
FBDD, within recent years organic synthesis has been identi-
fied as a significant bottleneck within this process, owing to 
the overrepresentation of predominantly ‘flat’ (het-
ero)aromatic fragments lacking three-dimensionality as well as 
synthetically tractable exit vectors that could be utilised in 
rapid structure-activity relationship (SAR) studies.
4,5,8
 Whilst 
complexity of fragments remains under debate within the liter-
ature,
9,10
 importantly, more three dimensional (3D) fragments 
displaying exit vectors increase the potential for multi-
directional fragment growth and the ability to identify leads 
for challenging targets such as protein-protein interactions.
8,11
 
Thus, recent efforts from within the synthetic community have 





Figure 1. A) Two FBDD-derived FDA-approved drugs: Veneto-
clax and Vemurafenib. B) Examples of spirocyclic natural prod-
ucts (Griseofulvin and Histrionicotoxin) and FDA-approved drugs 
(Spironolactone and Irbesartan). 
Spirocyclic motifs remain an important bioactive substruc-





 (Figure 1, B). Importantly, as a direct re-
sult of their architecture, these small molecules often provide 
several advantages.
21
 Firstly, the spiranic centre generates an 
inherently 3D structure that gives rise to higher levels of com-
plexity, a feature which has been linked to improved clinical 
success.
10,22,23
 Moreover, the conformationally restricted nature 
of spirocycles can reduce both the conformational entropy 
penalty of target binding and the number of possible confor-
mations (distinct 3D shapes) that a molecule can adopt leading 
to higher potency and selectivity, respectively.
24,25
 However, 
despite their utility, these motifs remain underrepresented in 
fragment screening collections. Indeed, very few compounds 
within the ChemBridge spirocycle library meet the size criteria 
of FBDD,
26,27
 whilst only three spirocycles feature within the 
Maybridge core fragment collection. Thus, there is an urgent 
need for spirocyclic fragments and calls from within the field 




Whilst strategies to access spirocycles within sp
3
-rich 
screening libraries have been reported, they either do not sole-
ly seek to construct spirocycles,
28–30





 spirocycles. In addition, these compounds 
often lie outside the requirements for FBDD. Thus, we envis-
aged that a novel approach to access diverse spirocyclic frag-
ments containing a polar heterocycle and a lipophilic carbocy-
cle could give rise to a valuable library complementing al-
ready existing screening collections. To achieve this, our ef-
forts were directed at utilising α,α-disubstituted amino acid 
derivatives as building blocks, providing the potential to ex-
ploit the functional handles to generate fragment-like spirocy-
clic scaffolds. The incorporation of the two alkene handles 
enabled the carbocycle formation via ring closing metathesis 
(RCM), forming an essential alkene exit vector, allowing us to 
alter the properties of this portion of the fragments. In addi-
tion, the amino and ester functionalities were installed to ena-
ble diverse heterocycle formations, increasing the possible 
polar interactions and the overall water solubility of the frag-
ments. Accordingly, rapid access to varied scaffolds and the 
potential to exploit the exit vectors for fragment growth and 
merging to aid hit-to-lead development was envisioned. 
Firstly, the building blocks were prepared through the dou-
ble alkylation of the glycine Schiff base 1 to form building 
blocks 3a-c (Scheme 1). Despite similar procedures have been 
reported before,
33–36
 herein we describe the straightforward 
racemic synthesis of α-quaternary amino esters with two dif-
ferent alkyl chains bearing terminal alkenes (3b,c). A brief 
optimisation of the related literature procedure
33
 allowed us to 
form 3c in a simple step-wise process. Further optimisation of 
the analogous route, however, resulted in the development of a 
one-pot procedure removing the chromatographic steps to 
access 3b on large-scale in an improved 61% yield. This  ap-
proach also enabled the formation of 3a. 
Scheme 1. Synthesis of the Building Blocks 
 
Reaction conditions: (i) tBuOK, THF; (ii) tBuOK, THF; (iii) 
HCl, THF/H2O; then Na2CO3. Overall yields: 3a: 67% (steps i 
and ii the same, steps i-iii in one-pot); 3b: 61% (steps i-iii in one-
pot); 3c: 31% (steps i-iii done step-wise). 
Subsequently, investigations into the formation of the dif-
ferent heterocycles were pursued using the racemic amino 
ester building block 3b. Firstly, the amine was Boc-protected 
to allow the cyclohexene formation in a RCM, followed by the 
reduction of the ester to the hydroxymethyl group by LiBH4 to 
afford the key intermediate 4 in good yield. Intramolecular 
base-mediated pairing between the alcohol and Boc groups 
could then be achieved forming the oxazolidone moiety in 5. 
The removal of the Boc protecting group under acidic condi-
tions could be followed by pairing reactions incorporating 
various reagents. Reaction with cyanogen bromide formed 
amino oxazoline 6 whereas ethyl benzimidate hydrochloride 
gave the phenyl-substituted oxazoline 7. The two morpho-
linones 8 and 9 were constructed by the chemoselective alkyl-
ation/acylation with chloroacetyl chloride and phenyl bromo-
acetate respectively (Scheme 2). 
Building block 3b could also be acylated with ethyl malonyl 
chloride, then the base-mediated cyclisation onto the ester 
group followed by the acid-catalysed decarboxylative hydroly-
sis yielded the tetramic acid intermediate 10b. Formation of 
the carbocycle ring in a RCM gave 12 in a good yield. To ex-
emplify the potential to expand the cyclohexene ring, spirocy-
cles also featuring the 5- and 7-membered carbocycles were 
also synthesised from 3a, and 3c respectively (Scheme 2). 
Importantly, all the spirocycles were synthesised in no more 
than five steps from the building blocks. 
Scheme 2. Synthesis of Different Core Heterocycles and 
Carbocycles 
 
Reaction conditions: a) (i) Boc2O, THF, 85%; (ii) Grubbs II, 
CH2Cl2, 81%; (iii) LiBH4, THF, 89%; b) tBuOK, THF, 90%; c) 
HCl, dioxane; then BrCN, Et3N, EtOH, 58%; d) HCl, dioxane; 
then ethyl benzimidate hydrochloride, Et3N, DCE, 57%; e) (i) 
HCl, dioxane; then chloroacetyl chloride, Et3N, CH2Cl2, 57%; (ii) 
tBuOK, tBuOH, 99%; f) HCl, dioxane; then phenyl bromoacetate, 
iPr2NEt, MeCN, 43%; g) (i) ethyl malonyl chloride, Et3N, 
CH2Cl2, 73–81%; (ii) tBuOK, THF; then aq. HCl, THF, 86–92%; 
h) Grubbs II, CH2Cl2, 69–99%. 
Although racemic compounds were sought for our fragment 
library, the ability to produce optically pure isomers e.g. for 
SAR studies was also crucial. Thus, a second asymmetric 
route to the desired building blocks was devised utilising the 
well-precedented stereoselective alkylation of iminolactones 
derived from phenylglycinol.
37,38
 In this case, only one dia-
stereomer of the aminolactone (R)-15 was observed, which 
was successively deprotected to form the optically pure build-
ing block (R)-3d. As proof of concept, the single R-
enantiomer of 12, with the spiro[4,5] scaffold, was also syn-
thesised (Scheme 3). 
Scheme 3. Enantioselective Synthesis of (R)-12 
 
Reaction conditions: a) allyl bromide, Zn, DMF, 68%; b) (i) 
SOCl2, MeOH; (ii) Pb(OAc)4, MeOH/CH2Cl2; then HCl, H2O, 
92% over 2 steps; c) (i) ethyl malonyl chloride, Et3N, CH2Cl2, 
46%; (ii) tBuOK, THF; then aq. HCl, THF, 92%; (iii) Grubbs II, 
CH2Cl2, 97%. 
With eight fragment scaffolds in hand, it was next crucial to 
demonstrate the utility of the exit vectors installed within the 
molecules. Thus, N-alkylation of the oxazolidone (16), O-
alkylation (17) and cross-coupling of the tetramic acid (18) 
were demonstrated. In addition, a modified heterocycle with 
an alcohol functionality (19) and two with new double bonds 
(20 and 21) were synthesised, incorporating new exit vectors 
to the resultant molecules (Scheme 4). 
Scheme 4. Heterocycle Modification 
 
Reaction conditions: a) PMBCl, NaH, DMF, 96%; b) KHMDS, 
EtBr, THF, 54%; c) (i) Tf2O, Et3N, CH2Cl2, 59%; (ii) 
PMPB(OH)2, Pd(PPh3)4, Na2CO3, H2O/THF, 73%; d) NaBH4, 
MeOH, 23%; e) TFAA, Et3N, CH2Cl2; then KHCO3, MeOH, 
30%; f) Pb(OAc)4, MeCN, 92%. 
Finally, to exhibit the versatility of the double bond as an 
exit vector, modifications such as Wacker-oxidation (22a,b), 
dihydroxylation (23a,b), difluoro-cyclopropanation (24a,b), 
aziridination (25a,b), epoxidation (26a,b) and dibromination 
(27a,b) were explored (Scheme 5). Initial attempts of the 
epoxidation of 5, however proved challenging with respect to 
the isolation and purification of 26a,b. Thus, a PMB group 
was installed (16) indeed proving to be compatible with sever-
al reaction conditions generating the diversified fragments in 
good to excellent yields. Removal of the PMB protecting 
group was also exemplified by the treatment of compound 27a 
with CAN to generate the unprotected modified spirocycle 28. 
Scheme 5. Double Bond Modification and PMB Deprotec-
tion 
 
R = PMB unless specified otherwise. All products are racemic. 
Reaction conditions (combined yields with ratios a/b are given): 
a) Fe(acac)2, tBuOH, air, 47%, 1.9:1; b) OsO4, NMO, citric acid, 
H2O/THF, 99%, 2.5:1; c) TMSCF3, NaI, THF, 62%, 20:1; d) 
TsNClNa.3H2O, PhNMe3Br3, 4 Å MS, 70%, 1.4:1;. e) R = H, 
mCPBA, NaHCO3, CH2Cl2, 52%, 8:1; f) PhNMe3Br3, CH2Cl2, 
96%, 18:1; g) CAN, MeCN/H2O, 96% (R = H in product). 
Table 1. Physicochemical Properties of Fragment Librar-
ies Compared to the Ideal Range 
propertya spirocyclesb Maybridgec ideal ranged 
MW 186 ± 41 182 ± 42 140–230 
HBD 1.3 ± 0.7 1.0 ± 0.8 ≤3 
HBA 1.8 ± 0.6 1.9 ± 0.7 ≤3 
SlogP 0.9 ± 0.9 1.8 ± 0.8 0–2 
RBC 0.2 ± 0.5 2.0 ± 1.5 ≤3 
TPSA 48 ± 13 39 ± 14 ≤60 
aMW = molecular weight (Da), HBD = number of hydrogen-
bond donors, HBA = number of hydrogen-bond acceptors, 
SlogP = partition coefficient, RBC = rotatable bond count, 
TPSA = topological polar surface area (Å2). bProtecting groups 
virtually removed from our library. cMaybridge core fragment 
collection of 1000 fragments. dGuidelines set by Astex Pharma-
ceuticals.26,27 See Supporting Information. 
The physicochemical properties of our library consisting of 
28 different non-protected spirocyclic molecules were then 
calculated and compared to the commercially available May-
bridge core fragment library using the widely-accepted guide-
lines from within the field (Table 1).
26,27
 This revealed the 
spirocyclic library adheres well to the guidelines, and was 
additionally predicted to be significantly less lipophilic (SlogP 
of 0.9 versus 1.8) and more rigid (rotatable bond count of 0.2 
versus 2.0) than the Maybridge core fragment collection. 
Strikingly, our library also displayed a far superior sp
3
-content 




) of 0.52, which 
also translates into a much lower fraction of aromatic atoms 
(Faro) of 0.16. Moreover, the average number of chiral centres 
(1.6) is also considerably higher, resulting in greater stereo-
chemical diversity achieved by the spirocyclic fragments. 
In order to qualitatively assess the shape diversity in our li-
brary, a principal moments of inertia (PMI) analysis was car-
ried out. Our library was then compared to the whole May-
bridge core fragment collection of 1000 fragments and a rep-
resentative subset consisting of the 147 best-matched com-
pounds based on heavy atoms (Figure 2). Both plots show that 
the Maybridge fragments tend to aggregate to the left-hand 
edge (rod- and disc-like features) or the ‘flat land’, whereas 
our spirocyclic fragments are more evenly distributed. Analy-
sis showed that more than 70% of the whole Maybridge col-
lection and 75% of the best formula match subset falls within 
‘flat land’ (defined as npr1 + npr2 ≤ 1.1).
11
 On the other hand, 
no spirocyclic fragment in our library was found below the 
‘flat land’ criteria, suggesting more 3D molecules. 
In conclusion, we have developed a robust, scalable and 
modular route to racemic α,α-disubstituted amino ester build-
ing blocks including an adapted stereoselective alkylation 
protocol to access the optically pure intermediate. These were 
utilised in the efficient construction of eight novel spirocyclic 
scaffolds comprising of pharmacophore heterocycles and vari-
able carbocycles. All core scaffolds display an array of 3D exit 
vectors demonstrated by a number of chemical modifications 
to both the hetero- and carbocycles. Together with the enanti-
oselective synthesis, rapid SAR studies and binding pocket 
exploration by fragment growth could therefore be envisioned. 
Finally, the computational predictions revealed optimal physi-
cochemical properties, higher rigidity increased 3D properties, 
shape and stereochemical diversity compared to a commercial 
fragment library. 
 
Figure 2. PMI plots for the visual representation of shape diversity. Each corner of the plot represents a unique shape (rod-, disk- and 
sphere-like features). The dashed line represents the boundary of ‘flat land’ 11. Our virtual deprotected library of 28 spirocycles (blue) is 
compared to 1000 fragments (red, left) and the 147 best-matched fragments based on heavy and heteroatom count (red, right) from the 
Maybridge collection. The table in the right summarises the physicochemical properties used to describe the 3D properties of the two li-
braries. aFsp3 = fraction of sp3 atoms, Far = fraction of aromatic atoms, chiral = number of chiral centres, npr = normalised PMI ratio, Fflat 
= fraction of molecules lying below the ‘flat land line’11. bVirtual deprotected library. c147 best-matched fragments from the Maybridge 
collection. See supporting information. 
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